EFFECT OF INTRAVENOUS IMMUNOGLOBULIN ON INFECTIONS IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING DARATUMUMAB
April 12th, 2021
Anti-CD38 monoclonal antibodies have led to improved response rates, progression-free and overall survival in randomized clinical trials (RCTs) of multiple myeloma (MM) patients. ... Read More
IN-CLASS TRANSITION (ICT) FROM PARENTERAL BORTEZOMIB...
April 12th, 2021
Long-term PI-based treatment is associated with improved outcomes in MM. Nonetheless, prolonged therapy with parenteral PIs (e.g. bortezomib) can be challenging in the real world, with median duration... Read More
METRONOMIC THERAPY FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
March 3rd, 2021
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In commodo vehicula velit, a vestibulum mi maximus in. Nulla at lectus tincidunt, mollis lectus vestibulum, congue metus. Morbi feugiat dolor s... Read More